KDMN News and Press, Kadmon Holdings Inc. From 02/23/20

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020 NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc. (NYSE:KD...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...

Kadmon Holdings (NYSE: KDMN ) is up 2.2% after hours following the acceptance of a late-breaking abstract of its trial of KD025 in chronic graft-versus-host disease for the 2020 Transplantation & Cellular Therapy Meetings. More news on: Kadmon Holdings, Inc., Healthcare stocks news...

NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that expanded data from the interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD), will be presented in a late-breaking oral pr...

BeyondSpring (NASDAQ: BYSI )  rises 2.7%  and Kadmon Holdings (NYSE: KDMN ) also  gains 2.7%  after Nomura Instinet initiates coverage of the two companies at Buy. More news on: BeyondSpring Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, Re...

Sorrento Therapeutics (NASDAQ: SRNE ) +50%  on non-binding takeover bid . More news on: Sorrento Therapeutics, Inc., Aclaris Therapeutics, Inc., AzurRx BioPharma, Inc., Stocks on the move, Read more ...

Aerie Pharmaceuticals (NASDAQ: AERI ) initiated with Neutral rating and $27 (6% upside) price target at Bank of America. More news on: Aurinia Pharmaceuticals Inc., BeyondSpring Inc., Cerecor Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Shares of Kadmon Holdings ( KDMN ) have risen by 29% since my 2017 ASH update highlighted mid-stage data for ROCK2 inhibitor KD025 in patients with chronic graft-versus-host disease (cGVHD). Shares have risen by 88% since my Buy recommendation in July, where I noted that completion of the ...

Kadmon Holdings (NYSE: KDMN ) and Meiji Seika Pharma ( OTC:MEJHF ) will form a joint venture to exclusively develop and commercialize KD025 in Japan and certain other Asian countries. More news on: Kadmon Holdings, Inc., Meiji Holdings Co., Ltd., Healthcare stocks news, Read more ......